Status:
UNKNOWN
Red Light Intervention on Myopic Progression
Lead Sponsor:
Shanghai Eye Disease Prevention and Treatment Center
Conditions:
Myopia
Eligibility:
All Genders
6-12 years
Phase:
NA
Brief Summary
To explore the effectiveness of using repeated low-level red-light therapy to slow myopia progression.
Eligibility Criteria
Inclusion
- Age at enrolment: 6-12 years;
- At least one eye with spherical equivalent refractions (SERs): -1.00 to -5.00 diopters (D), and stigmatism of 1.50 D or less;
- Anisometropia of 1.5 D or less;
- The BCVA of distant vision is at least 0.8;
- Myopia progressed more than 0.5D in the past year;
- Have normal thinking and language communication skills, and be able to actively cooperate with the treatment as required;
- Written informed consent of guardian and child.
Exclusion
- Strabismus, amblyopia or other ocular abnormalities;
- Other systemic abnormalities;
- Prior treatment of myopia control in 6 months, e.g. drugs, orthokeratology, progressive addition lenses, bifocal lenses, etc in either eye;
- Atropine allergy;
- Other situations that not suitable for participating in the trial as judged by the researcher.
Key Trial Info
Start Date :
February 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT05203432
Start Date
February 10 2022
End Date
June 30 2024
Last Update
October 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Eye Disease Prevention and Treatment Center
Shanghai, China, 201103